Aras Azadian

CBD-Focused Avicanna Reports First-Ever Adjusted EBITDA Positive Quarter, 451% YoY Spike In Q1 Record Revenue
Cannabinoid-Based Products Maker Sees Triple-Digit Growth In 2023 Gross Profit, Revenue Surges 314% YoY
Can Cannabis Treat Severe Forms Of Epilepsy? New Medicine Sparks Hope As Colombia's Weed Industry Goes Global
Cannabinoid-Based Products Maker Sees Triple-Digit Growth In 2023 Gross Profit, Revenue Surges 314% YoY
Can Cannabis Treat Severe Forms Of Epilepsy? New Medicine Sparks Hope As Colombia's Weed Industry Goes Global
CBD-Focused Avicanna Taps Into European Market Via Exclusive Pharma Supply Deal
Avicanna Inc.: Medical Marijuana Sales Reach Record 713% YoY Growth In Q3, Introduces New Platform

Aras Azadian Recent News

Avicanna Reveals The Initial Network Of Brands On Its Cannabis Care Platform
Avicanna Inc. (OTCQX: AVCNF) (TSX:AVCN) (FSE:0NN) a biopharmaceutical company focused on the development, manufacturing and commercialisation of plant-derived cannabinoid-based products announced its initial portfolio offering and network in anticipation of the MyMedi.ca platform’s launch in e
Two Pot Companies Continue To Focus On Cannabinoid-Based Self-Emulsifying Drug Delivery Systems
Avicanna Inc. (OTCQX: AVCNF) (TSX:AVCN) (FSE:0NN) announced the extension of its existing strategic manufacturing agreement with Medipharm Labs Inc. (OTCQB: MEDIF) for the commercialization of Avicanna’s p
Avicanna And Northern Green Canada Execute Master Service Agreement To Operationalize MyMedi.ca
Avicanna Inc. (OTCQX: AVCNF) (TSX:AVCN) (FSE:0NN) has entered into a master service agreement with Northern Green Canada to operationalize MyMedi.ca medica
Avicanna FY22 Revenue Grows 24%, Here Is What You Need To Know
Avicanna Inc. (TSX:AVCN) (OTCQX: AVCNF) (FSE:0NN) total fiscal 2022 revenue of CA$4 million representing growth of 24% from CA$3.3 million in fiscal 2021.
Avicanna Stock Jumps On Partnership With Shoppers Drug Mart
Shoppers Drug Mart has selected Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) as its partner to transition its Medical Cannabis by Shoppers business.
Avicanna Expands Its Pact With Al Harrington's Viola Brands To The UK
Avicanna Inc. (OTCQX: AVCNF) (TSX:AVCN) (FSE:0NN) has entered into a new sub-license agreement with VB Brands California LLC and Player Holdings LLC to exclusively commercialize its Viola-branded products in the United Kingdom territory where the company ha
These 9 Cannabis Companies Are Leading The Way In Latin America: What Are They Up To And Why Should You Pay Attention?
The Benzinga Cannabis Capital Conference in Chicago, September 13-14, will celebrate the most recognized Latin American cannabis companies.
Avicanna Reports Q2 2022 Earnings: Over 100% Increase From Last Year, Meet CEO At Benzinga Cannabis Capital Conference
Avicanna (OTCQX: AVCNF), a biopharmaceutical company focused on cannabinoid-based products, released its Q2 2022 highlights:
Avicanna, Ei. Ventures Partner To Develop And Launch Functional Fungi-Based Products
Avicanna Inc. (OTCQX: AVCNF) (TSX:AVCN) (FSE: 0NN) a biopharmaceutical company focused on the development, manufacturing, and commercialization of plant-derived cannabinoid-based products has entered into an intellectual
EXCLUSIVE: How Avicanna Is Advancing Plant-Derived, Cannabinoid-Based Products
Regulation is among the factors inhibiting the flow of capital to cannabis innovation. Institutions are afraid to invest, and “big pharma is not coming in as we would like to see happen.”
Breaking: Avicanna's Cannabinoid Drugs To Reach Brazil Via Its First 'Big Pharma' Deal
Avicanna's CBD Derma-Cosmetics To Reach European Union Market Via Bio-Gate Partnership
Tetra Bio-Pharma & Avicanna Enter Into Strategic Partnership
Tetra Bio-Pharma Inc. (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) announced that it has executed a non-binding term sheet with Avicanna Inc.
Avicanna Provides Q4-2021 Results And Fiscal 2022 Guidance
Avicanna Inc. (TSX:AVCN) (OTCQX: AVCNF) (FSE:0NN) provided fourth quarter 2021 results and highlights, as well as fiscal 2022 guidance.
Lab-Grown Cannabinoids: Is The Cannabis Market Ready?
Original publication date: November 9, 2020 4:30 pm
Cannabis Movers & Shakers: Aurora Bolsters Management, Curaleaf Names New Pres, Verano & Avicanna's New Appointments
Aurora Announces Changes To Management Team
Avicanna Debuts CBD Derma-Cosmetics Pura H&W In US Via Deal With Red White & Bloom
Cannabis-focused biopharmaceutical company Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) announced on Wednesday the
Avicanna & Al Harrington's CBD Wellness Launch New Sports Recovery-Based CBD Brand re+PLAY
Cannabis-focused biopharmaceutical company Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE:0NN) announced on Monday the launch of re+PLAY sports recovery-based CBD brand through a partnership with Harrington Wellness, founded by NBA veteran Al Harrington.
Cannabis Movers & Shakers: Aurora Cannabis, Dama Financial, Neptune Wellness, Avicanna
Dama Financial Appoints Industry Veteran Ed Labry As Executive Chairman Of Board Dama Financial, a provider of access to financial services for the cannabis industry, said Wednesday that it has named industry veteran Ed Labry as executive chairman of the board.
Avicanna's CEO Touts Q3 As 'Most Successful Quarter To Date' As It Posts Record Results, Expands Into 12th International Market
CBD-focused biopharmaceutical company Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE:0NN) reported its third-quarter financial results Friday, revealing a gross revenue increase of 24% sequentially and 260% compared to the first three months of 2021 to roughly CA$1,007,033 ($987,967)
Cannabis Movers & Shakers: Synendos Therapeutics, Rapid Therapeutic Science Laboratories, Palo Santo, Avicanna
Synendos Therapeutics Appoints CNS Experts To Advisory Board Synendos Therapeutics, a biopharmaceutical company focused on restoring the natural functioning of the endocannabinoid system to treat central nervous system disorders, recently announced the appointment of CNS experts to form its scientific advisory board.
Avicanna Files Patent For New Cannabinoid-Based Epilepsy Medication
Avicanna Inc., (TSX: AVCN) (OTCQX: AVCNF) a biopharmaceutical company focused on cannabinoid-based medicines, has filed a provisional patent application that aims to patent the use of a novel cannabinoid formulation for reducing or eliminating seizures and sudden death in epilepsy.